Vedolizumab gets edge in IBD head-to-head

But did the trial design skew results?

A head-to-head comparison of adalimumab and vedolizumab for the treatment of ulcerative colitis finds vedolizumab is superior for clinical remission and endoscopic improvement, but not in achieving corticosteroid remission.

IV infusion bag

The double-blinded trial — known as VARSITY and funded by Takeda, the maker of vedolizumab — was carried out in 245 centres across 34 countries, including Australia.

Nearly 770 patients with moderate to severe disease were randomised to the two biologics, with major endpoints assessed after a year on treatment.

Latest

Trending